Stay updated on SAGE-547 for Super-Refractory Status Epilepticus Clinical Trial

Sign up to get notified when there's something new on the SAGE-547 for Super-Refractory Status Epilepticus Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SAGE-547 for Super-Refractory Status Epilepticus Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs; the page still displays a 403 error instead of the study record.
    Difference
    1%
    Check dated 2026-10-24T12:04:12.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T13:13:58.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.0 to v3.7.1, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T13:52:51.000Z thumbnail image
  4. Check
    37 days ago
    Change Detected
    Summary
    A 403 Forbidden page is now shown where the study content would be, indicating the page is blocked from loading the trial information.
    Difference
    16%
    Check dated 2026-09-19T19:21:36.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    Tel Litwinsky (Israel, 52621) has been added to the list of study sites, while Qiryat Krinitzi (Israel, 52621) has been removed. This reflects an update to the participating locations for the study in Israel.
    Difference
    0.0%
    Check dated 2026-09-12T18:26:35.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    A new site entry for Qiryat Krinitzi, Israel, 52621 was added, and Tel Litwinsky, Israel, 52621 was removed from the study locations. This indicates a relocation/expansion of Israel-based sites for the SRSE trial, affecting candidate access and site management.
    Difference
    0.0%
    Check dated 2026-09-05T19:31:06.000Z thumbnail image

Stay in the know with updates to SAGE-547 for Super-Refractory Status Epilepticus Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SAGE-547 for Super-Refractory Status Epilepticus Clinical Trial page.